Microsoft word - october 2013 flyer.doc

PRESENTS:
“RESIDENT SEMINARS 2013”
DATE AND TIME:
12 p.m. – 5:35 p.m.
Doors open 15 minutes before the first program. Seating may be limited for some sessions. LOCATION:

PARKING:
St. Louis College of Pharmacy Parking Garage.
TARGET AUDIENCE:

REGISTRATION:
www.stlcop.edu/ce (all participants are encouraged to register in advance) These programs will update the participant on a variety of emerging pharmacy topics.
SPEAKERS:
All program speakers are completing a pharmacy residency
FACULTY DISCLOSURE:
Faculty for these programs report no actual or potential conflicts of interest related to their programs.
SUPPORTED:
No outside support was provided for these presentations.
PROGRAM SPECIFICS:
The next page of this document has a schedule with location and titles for the day’s events. For a list of the ACPE UAN#s and the program objectives, please review pages 3 - 6. Any questions may be direct to Erika Michalski, Director, Office of Continuing Professional Development: Erika.Michalski@stlcop.edu or 314.446.8539
ACCREDITATION STATEMENT:
St. Louis College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists participating in this program can receive up to 5 contact hours (0.5 CEU) of continuing pharmacy education. Some sessions are knowledge-based and others are application-based. Confirmation of attendance will be sent by St. Louis College of Pharmacy on behalf of participants to the NABP through the CPE Monitor system. Please be sure to bring your CPE Monitor ID number with you and include it on the sign-in sheets for the various sessions you attend. It is the policy of St. Louis College of Pharmacy, Department of Professional Development, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in this program are expected to disclose to the program audience any real or apparent conflicts of interest related to the content of the presentation. ACPE UAN#’s are listed with each presentation on the schedule. October 25, 2013 Seminar Schedule
1336 1337 1390 1503
Travel Time: In an effort to accommodate those traveling between the 3rd floor and the 5th floor for presentations, we have added a brief break
Marianna Fedorenko, PharmD Amanda Buckallew, PharmD 2:05 – 2:10 pm Travel Time: In an effort to accommodate those traveling between the 3rd floor and the 5th floor for presentations, we have added a brief break
3:10 – 3:30 pm Break: Please join your colleagues on the 3rd floor of Jones Hall for some light refreshments.
4:30 – 4:35 pm Travel Time: In an effort to accommodate those traveling between the 3rd floor and the 5th floor for presentations, we have added a brief break
Information for 12 pm Sessions
Waiting for an Antidote: Management of Bleeding Secondary to Oral Antithrombotics, presented by Jera Wilburn, PharmD from Christian Hospital
ACPE UAN: 0033-0000-13-108-L01-P;
Objectives: At the completion of this activity, the participant will be able to 1. Compare different strategies for the management of bleeds associated with new oral anticoagulants dabigatran, rivaroxaban, and apixaban 2. Analyze the mechanisms of action of new antidotes in development for reversal of oral anticoagulant-associated bleeds 3. Develop management strategies for acute bleeding associated with dabigatran, rivaroxaban, and apixaban Role of TNF-alpha antagonist therapy in sarcoidosis, presented by Gretchen Stern, PharmD from STLCOP/Mercy Hospital ACPE UAN: 0033-0000-13-109-L01-P; Objectives: At the completion of this activity, the participant will be able to 1. Explain the MOA of TNF-alpha antagonists in the treatment of sarcoidosis 2. Identify serious adverse effects associated with anti-TNF-alpha therapy 3. Describe sarcoidosis patients that would be good candidates for TNF-alpha antagonist therapy The Role of Sofosbuvir in the Treatment of Hepatitis C, presented by Nicole Gibson, PharmD from STLCOP/Walgreens ACPE UAN: 0033-0000-13-110-L01-P; Objectives: At the completion of this activity, the participant will be able to
1. Review the epidemiology, pathophysiology, risk factors, and efficacy endpoints for the treatment of hepatitis C
2. Discuss the current recommendations in the American Association for the Study of Live Diseases (ASSLD) practice guidelines
3. Explain the potential role of sofosbuvir in the treatment of hepatitis C based upon available literature
Information for the 1:05 pm Sessions
Predicting the clinical role of novel beta-lactamase inhibitors, presented by Marianna Fedorenko, PharmD from Barnes-Jewish Hospital
ACPE UAN: 0033-0000-13-111-L01-P;
Objectives: At the completion of this activity, the participant will be able to 1. Summarize the limitations of current treatment options for extended spectrum beta-lactamases and carbapenemases 2. Compare and contrast the microbiological spectrum of activity for novel beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations 3. Identify the potential niche for novel BL/BLI combinations The use of triple antithrombotic therapy in patients with atrial fibrillation with recent percutaneous intervention, presented by Amanda Buckallew, PharmD from Missouri Baptist Medical Center ACPE UAN: 0033-0000-13-112-L01-P; Objectives: At the completion of this activity, the participant will be able to 1. Define the role of anticoagulation therapy for stroke prevention in percutaneous intervention (PCI) 2. Define current recommendations regarding triple anticoagulation therapy in PCI 3. Discuss literature to assess the safety and efficacy of triple therapy in patients with PCI 4. Describe risks and benefits of triple therapy to select optimal antithrombotic therapy Expanding the role of TPA in Stroke presented by Nicholas W. Van Hise, PharmD STLCOP/Mercy Hospital ACPE UAN: 0033-0000-13-113-L01-P; Objectives: At the completion of this activity, the participant will be able to 1. Explain the rationale behind using rt-PA in wake up stroke 2. Describe trials for the use of rt-PA after 4.5 hours and wake up stroke 3. Identify patients that may be candidates to safely use rt-PA Information for the 2:10 pm Sessions
Management of Carbapenem-Resistant Enterobacteriaceae (CRE) infections, presented by Aditya Thaker, PharmD from St. Luke’s Hospital
ACPE UAN: 0033-0000-13-114-L01-P;
Objectives: At the completion of this activity, the participant will be able to 1. Identify the increasing prevalence of carbapenem resistance and efforts to contain the spread of infections 2. Discuss the CRE treatment options, including safety, efficacy, and agents used for specific infection site 3. Evaluate primary literature comparing combination therapy versus monotherapy for treatment of CRE infections Blood Pressure Control in Intracranial Hemorrhage, presented by Emily J. Owen, PharmD from St. Louis University Hospital ACPE UAN: 0033-0000-13-115-L01-P; Objectives: At the completion of this activity, the participant will be able to 1. Explain the physiologic changes in cerebral autoregulation in response to an intracerebral hemorrhage 2. Identify the current guideline recommendations for the control of blood pressure in intracerebral hemorrhage 3. Discuss currently available literature pertaining to blood pressure control in intracerebral hemorrhage Tyrosine Kinase Inhibitors and Hematopoietic Stem Cell Transplantation, presented by Adrienne Nedved, PharmD, MPA from Barnes-Jewish Hospital ACPE UAN: 0033-0000-13-116-L01-P; Objectives: At the completion of this activity, the participant will be able to 1. Describe the current practice guidelines for tyrosine kinase inhibitor use in ALL and CML 2. Describe the safety and efficacy of tyrosine kinase inhibitors post-transplant Incidence of pancreatitis and pancreatic cancer in glucagon-like peptide 1 mimetics and dipeptidyl peptidase 4 inhibitors: cause for concern? presented by Jena Torpin, PharmD from UMHC ACPE UAN: 0033-0000-13-117-L01-P; Objectives: At the completion of this activity, the participant will be able to
1. Discuss the current ADA guidelines for the treatment of type II diabetes
2. Analyze the recent safety concerns of incretin mimetic therapies
3. Identify the role of incretin mimetics in the treatment of type II diabetes
Information for the 3:30 pm Sessions
The Use of Colistin for Multidrug-Resistant Gram-Negative Organisms, presented by Lindsay Rippelmeyer, PharmD from St. Louis University Hospital
ACPE UAN: 0033-0000-13-118-L01-P;
Objectives: At the completion of this activity, the participant will be able to 1. Explain the pharmacologic properties of colistin 2. Discuss the trials describing the pharmacokinetics of colistin in critically ill patients 3. Describe the clinical outcome trials evaluating the use of colistin in patients with infections due to MDR gram negative organisms 4. Determine appropriate colistin therapy for patients with infections due to multi-drug resistant Gram-negative bacteria The Use of Erythropoietin-Stimulating Agents in the Treatment of Anemia in Patients with Heart Failure, presented by Ashley Sadowy, PharmD from VA St. Louis Healthcare System ACPE UAN: 0033-0000-13-119-L01-P; Objectives: At the completion of this activity, the participant will be able to 1. Compare and contrast treatment modalities available for anemia in patients with heart failure 2. Describe the safety and efficacy of erythropoietin-stimulating agents in the treatment of anemia in patients with heart failure 3. Recommend appropriate therapy for anemia in patients with heart failure using available literature Fungal Prophylaxis in Pediatric Oncology and Bone Marrow Transplant Patients, presented by Jonna Vick, PharmD from St. Louis Children’s Hospital ACPE UAN: 0033-0000-13-120-L01-P; Objectives: At the completion of this activity, the participant will be able to 1. Differentiate between prophylactic, empiric, and preemptive therapy 2. Discuss the relevant controversies that exist within the guidelines (NCCN and IDSA) 3. Explain why medication need to have therapeutic drug monitoring (in terms of pharmacologic properties and outcomes associated with infection in the literature) Chemotherapy dosing in obese patients, presented by Beejal Ruparelia Ganti, PharmD from UMCH ACPE UAN: 0033-0000-13-121-L01-P; Objectives: At the completion of this activity, the participant will be able to 1. Discuss the controversy for dosing chemotherapy in obese patients 2. Describe studies in solid tumors describing the relationship between chemotherapy dosing, toxicity, and outcomes in obese patients 3. Describe the American Society for Clinical Oncology (ASCO) guidelines for chemotherapy dosing in obese patients 4. Describe studies in hematological malignancies published after the development of guidelines Hepatitis C recurrence after liver transplant: management and treatment challenges in the new era of antivirals, presented by Elizabeth Shipulina, PharmD from Barnes-Jewish Hospital ACPE UAN: 0033-0000-13-122-L01-P; Objectives: At the completion of this activity, the participant will be able to
1. Summarize current challenges in treatment of hepatitis C after liver transplantation
2. Describe differences in safety and efficacy between antivirals in transplant patients
3. Identify an appropriate recommendation for use of antivirals in the treatment of recurrent hepatitis C post liver transplantation
Information for the 4:35 pm Sessions
Dosing of Selected Beta-Lactam and Fluoroquinolone Antibiotics in Obese Patients, presented by Danny Ephraim, PharmD from Missouri Baptist Medical Center
ACPE UAN: 0033-0000-13-123-L01-P;
Objectives: At the completion of this activity, the participant will be able to 1. Discuss pharmacokinetic and pharmacodynamic principles in obese patients 2. Identify pharmacokinetic and pharmacodynamic principles of beta-lactams and fluoroquinolones 3. Analyze pertinent literature to assess the safety and efficacy of antibiotic dosing strategies in obese patients 4. Select and recommend a safe and efficacious dosing regimen for antibiotics in obese patients Warfarin: What’s in a Loading Dose? presented by Breann Williams, PharmD from VA St. Louis Healthcare System ACPE UAN: 0033-0000-13-124-L01-P; Objectives: At the completion of this activity, the participant will be able to 1. Describe the hypercoaguable state that occurs during warfarin initiation, including effects of and timing of changes in coagulation factors (II, IV, IX, X, C, S) 2. Compare and contrast the results of clinical studies evaluating strategies for dosing during warfarin initiation – specifically for use of initial loading doses of warfarin versus use of initial maintenance doses of warfarin 3. Explain how patient specific characteristics influence decisions on initial warfarin dosing Management of Nutritional Requirements in Preterm Neonates presented by Caren Liviskie, PharmD from St. Louis Children’s Hospital ACPE UAN: 0033-0000-13-125-L01-P; Objectives: At the completion of this activity, the participant will be able to 1. Identify the nutritional needs of a preterm neonate and potential adverse outcomes 2. Identify the components of parenteral nutrition 3. Describe the literature pertaining to the outcomes of early, aggressive parenteral nutrition in preterm neonates Analgosedation: No Pain, All Gain presented by Scott Nei, PharmD from Barnes-Jewish Hospital ACPE UAN: 0033-0000-13-126-L01-P; Objectives: At the completion of this activity, the participant will be able to 1. Review the trends of sedation over the past 15 years 2. Explain the complication related to inadequate pain control 3. Evaluate the difference between analgesia-based sedation and hypnotic-based sedation 4. Compare/contrast the different agents for analgesia-based sedation Big People, Little Bugs: Dosing MRSA Antibiotics in the Obese Patient presented by Chelsey Imel, PharmD from St. Mary’s Health Center ACPE UAN: 0033-0000-13-127-L01-P; Objectives: At the completion of this activity, the participant will be able to 1. Review vancomycin, daptomycin, and linezolid as MRSA antibiotics 2. Explain possible barriers to adequate MRSA antibiotic dosing in the obese patient 3. Propose an appropriate vancomycin, daptomycin, or linezolid MRSA antibiotic dosing recommendation for an obese patient

Source: https://ce.stlcop.edu/uploads/366/October%202013%20Flyer.pdf